We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+6.58%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$333M
AUM Growth
+$77.5M
Cap. Flow
+$78M
Cap. Flow %
23.42%
Top 10 Hldgs %
35.62%
Holding
104
New
20
Increased
33
Reduced
37
Closed
13

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$11.1M
2
GILD icon
Gilead Sciences
GILD
+$11M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$9.82M
4
MDVN
MEDIVATION, INC.
MDVN
+$7.71M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$5.79M

Top Sells

Rank Stock Value
1
INVA icon
Innoviva
INVA
+$4.71M
2
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$3.6M
3
ISRG icon
Intuitive Surgical
ISRG
+$3.07M
4
ZBH icon
Zimmer Biomet
ZBH
+$2.8M
5
AET
Aetna Inc
AET
+$2.74M

Sector Composition

Rank Sector Weight
1 Healthcare 79.75%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABMD
51
DELISTED
Abiomed Inc
ABMD
$2.34M 0.7%
89,916
+24,916
+38% +$689K
STJ
52
DELISTED
St Jude Medical
STJ
$2.25M 0.68%
34,394
-5,606
-14% -$365K
DVAX
53
DELISTED
Dynavax Technologies
DVAX
$2.21M 0.66%
122,835
-17,165
-12% -$318K
NKTR icon
54
Nektar Therapeutics
NKTR
$2.58B
$2.2M 0.66%
12,120
-547
-4% -$108K
RAD
55
DELISTED
Rite Aid Corporation
RAD
$2.16M 0.65%
+17,240
New +$2.1M
OREX
56
DELISTED
Orexigen Therapeutics, Inc.
OREX
$2.14M 0.64%
32,920
+7,920
+32% +$536K
ELV icon
57
Elevance Health
ELV
$85.5B
$2.13M 0.64%
40,000
+8,000
+25% +$724K
VAR
58
DELISTED
Varian Medical Systems, Inc.
VAR
$2.04M 0.61%
38,773
-1,140
-3% -$82.1K
CPHD
59
DELISTED
Cepheid Inc
CPHD
$2.03M 0.61%
39,308
+9,308
+31% +$473K
BAX icon
60
Baxter International
BAX
$14.2B
$1.98M 0.6%
77,633
+9,516
+14% +$356K
ARIA
61
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$1.92M 0.58%
237,810
-462,190
-66% -$3.6M
JNJ icon
62
Johnson & Johnson
JNJ
$625B
$1.91M 0.57%
19,481
-10,519
-35% -$975K
HPTX
63
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
$1.9M 0.57%
73,702
-36,298
-33% -$983K
ITCI
64
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$1.79M 0.54%
+98,269
New +$1.77M
SUPN icon
65
Supernus Pharmaceuticals
SUPN
$2.77B
$1.76M 0.53%
196,537
-28,463
-13% -$262K
MASI
66
DELISTED
Masimo
MASI
$1.74M 0.52%
+63,875
New +$1.82M
AUXL
67
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$1.74M 0.52%
63,875
-21,125
-25% -$561K
ECYT
68
DELISTED
Endocyte, Inc. Common Stock
ECYT
$1.64M 0.49%
68,788
+43,788
+175% +$635K
COR icon
69
Cencora
COR
$61.2B
$1.64M 0.49%
35,000
-5,000
-13% -$340K
UHS icon
70
Universal Health Services
UHS
$10.5B
$1.61M 0.48%
+19,654
New +$1.58M
BDX icon
71
Becton Dickinson
BDX
$48.2B
$1.59M 0.48%
24,600
-1,025
-4% -$113K
CFN
72
DELISTED
CAREFUSION CORPORATION
CFN
$1.58M 0.47%
+39,308
New +$1.59M
RVNC
73
DELISTED
Revance Therapeutics, Inc.
RVNC
$1.55M 0.46%
+49,135
New +$1.54M
ARRY
74
DELISTED
Array Biopharma Inc
ARRY
$1.55M 0.46%
329,199
-30,801
-9% -$155K
CLDX icon
75
Celldex Therapeutics
CLDX
$3.28B
$1.3M 0.39%
4,913
-1,087
-18% -$416K
1 2
3
4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2014 Portfolio in Review

As of Q1 2014, Rhenman & Partners Asset Management held 104 positions worth $333M, up 30% from $256M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Rhenman & Partners Asset Management deployed $78M of net new capital in Q1 2014, opening 20 new positions and adding to 33 existing holdings. Its largest new stake was Pfizer: 372,050 shares worth $11.3M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 83% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Ariad Pharmaceuticals Inc, an estimated $3.6M trimmed.

  • Rhenman & Partners Asset Management's largest Q1 2014 buy was Pfizer: 372,050 shares worth $11.3M.
  • Rhenman & Partners Asset Management added most to Gilead Sciences in Q1 2014, an estimated $11M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2014 reduction was Ariad Pharmaceuticals Inc, cutting an estimated $3.6M.
  • Rhenman & Partners Asset Management fully exited Innoviva in Q1 2014, selling an estimated $4.71M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 36% of its $333M portfolio in Q1 2014.
  • Rhenman & Partners Asset Management opened 20 new positions and closed 13 in Q1 2014.
  • Rhenman & Partners Asset Management's portfolio value rose 30% quarter-over-quarter to $333M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2014, filed 14 May 2014.